$695 | Single User
$1395 | Global License

Physician Views: When and where do oncologists see palbociclib fitting into the ER+, HER2- breast cancer landscape?

Published by FirstWord Pharma: 28 Aug 2014 | 152 | In Stock

Introduction

Scope



Analysts believe palbociclib is likely headed for an accelerated approval to treat a subset of breast cancer, which would give Pfizer a big leg up over competitors like Eli Lilly and Novartis with less advanced compounds in the CDK 4/6 inhibitor class.


Expectations for palbociclib were flying high in 2012 when Pfizer reported preliminary results from the Phase II PALOMA-1 trial showing the drug improved progression-free survival (PFS) by 18.6 months when added to Femara in postmenopausal women with oestrogen receptor (ER) positive, HER2-negative locally advanced or metastatic breast cancer (26.1 months versus 7.5 months). In fact, the FDA found the early data compelling enough to grant the product breakthrough therapy status last year.


However, the waters were muddied this spring by updated PALOMA-1 results that were seen as a disappointment by many on the Street. Specifically, palbociclib's PFS advantage had narrowed considerably to only 10 months, while an interim look at the secondary endpoint of overall survival (OS) showed the compound failed to achieve significance (37.5 months for the combination versus 33.3 months for Femara alone).


The lack of improvement on the OS endpoint appeared to catch many by surprise given palbociclib's particular robust impact on PFS. Nonetheless, after discussions with the FDA, Pfizer announced its intentions to submit a filing for palbociclib this quarter, though the company declined to share whether the decision was being driven by itself or the agency. Either way, Pfizer followed through on the plan andcompleted submission of the application earlier this month.


Jefferies analyst Jeffrey Holford suggested the strong PFS data and "consistent improvement across other efficacy measures," along with a relatively clean safety profile strengthen Pfizer's case for approval of palbociclib.


Approval based on PALOMA-1 alone would be an important achievement for Pfizer. Analysts predict marketing applications for its closest competitors, such as Eli Lilly's bemaciclib and Novartis' LEE011, will not be ready before at least 2016, meaning the sooner palbociclib is approved the stronger foothold it will have.


Puchase Reasons


Thus, to better understand the likelihood of an accelerated approval of palbociclib, as well as how it might fit into the commercial setting, FirstWord is this week polling US-based oncologists. Specifically we are asking them...


  • Given the small size (165 patients) and open-label design of the Phase II PALOMA-1 study, combined with the non-significant difference on overall survival at the interim update this spring, are the data showing palbociclib improved progression-free survival by 10 months in ER+, HER2- breast cancer patients sufficient to support an accelerated approval in this setting?

  • Based on previous experiences in this setting, such as iniparib (Phase II data failed to translate to OS benefit in Phase III) and Avastin (accelerated approval based on PFS later revoked when it did not improve OS), would the FDA be right to wait for data confirming a survival advantage before approving palbociclib in this setting?

  • Based on the data available for various CDK 4/6 inhibitors (eg, Eli Lilly's bemaciclib and Novartis' LEE011), how does Pfizer's palbociclib appear to stack up and what impact will this have on how much use it receives?

  • Does use of Femara (letrozole) in the adjuvant setting make the results of PALOMA-1 difficult to interpret?

  • What percentage of front-line patients with ER+, HER2- breast cancer do you expect to use palbociclib in 12 months from now?
  • Table of Contents
    for Physician Views: When and where do oncologists see palbociclib fitting into the ER+, HER2- breast cancer landscape?

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    152 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market?
    ScopeBased on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later thi...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?
    ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
    ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Post ADA view on key diabetes market developments
    ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready?
    ScopeThe recent recommendation to approve a biosimilar version of Merck & Co./Johnson & Johnson's Re...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor?
    ScopeAs GlaxoSmithKline's Relvar Ellipta – a once-daily successor to its multi-billion dollar Sereti...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
    ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
    ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Surveying Physician Uptake of Mobile Devices and Apps
    IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo...
    01 Oct 2012 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Physician Views: When and where do oncologists see palbociclib fitting into the ER+, HER2- breast cancer landscape? | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...

    • Allied Market Research
    • CBR Pharma
    • Current Partnering
    • Firstword
    • Global Data
    • Global Markets Direct
    • ICD Research
    • Infinti Research Technavio
    • Marketline
    • Markets and Markets
    • Micro Markets Monitor
    • MP Advisors
    • Venture Planning Group
    • GMR Data